A new standard of care for patients with surgically unresectable stage III non-small cell lung cancer

被引：2

作者：

Gill, Harpaul S. ^{[1
]}

Ramalingam, Suresh S. ^{[1
]}

机构：

[1] Emory Univ, Sch Med, Dept Hematol & Oncol, Winship Canc Inst, 1365 Clifton Rd NE,Bldg C,Suite 4014, Atlanta, GA 30322 USA

来源：

CANCER | 2019年 / 125卷 / 13期

关键词：

durvalumab; immune checkpoint inhibition; NSCLC; PACIFIC trial; stage III NSCLC; RANDOMIZED PHASE-III; RADIATION-THERAPY; CONCURRENT CHEMORADIOTHERAPY; SEQUENTIAL CHEMORADIOTHERAPY; CONSOLIDATION DOCETAXEL; THORACIC RADIOTHERAPY; TRIAL; CHEMOTHERAPY; COMBINATION; CARBOPLATIN;

D O I：

10.1002/cncr.31996

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Overall survival data from the PACIFIC trial have reaffirmed earlier US Food and Drug Administration approval of durvalumab in patients with stage III non-small cell lung cancer. In the current commentary, the authors provide a brief historical perspective on stage III disease as well as a further analysis of the strengths and weaknesses of the trial.

引用

页码：2148 / 2153

页数：6

共 63 条

[1] Systematic review of case reports on the abscopal effect [J].

Abuodeh, Yazan ;

Venkat, Puja ;

Kim, Sungjune .

CURRENT PROBLEMS IN CANCER, 2016, 40 (01) :25-37

[2]

[Anonymous], 2018, J CLIN ONCOL S

[3] Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC [J].

Antonia, S. J. ;

Villegas, A. ;

Daniel, D. ;

Vicente, D. ;

Murakami, S. ;

Hui, R. ;

Kurata, T. ;

Chiappori, A. ;

Lee, K. H. ;

de Wit, M. ;

Cho, B. C. ;

Bourhaba, M. ;

Quantin, X. ;

Tokito, T. ;

Mekhail, T. ;

Planchard, D. ;

Kim, Y. -C. ;

Karapetis, C. S. ;

Hiret, S. ;

Ostoros, G. ;

Kubota, K. ;

Gray, J. E. ;

Paz-Ares, L. ;

Carpeno, J. de Castro ;

Faivre-Finn, C. ;

Reck, M. ;

Vansteenkiste, J. ;

Spigel, D. R. ;

Wadsworth, C. ;

Melillo, G. ;

Taboada, M. ;

Dennis, P. A. ;

Ozguroglu, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (24) :2342-2350

[4] Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer [J].

Antonia, S. J. ;

Villegas, A. ;

Daniel, D. ;

Vicente, D. ;

Murakami, S. ;

Hui, R. ;

Yokoi, T. ;

Chiappori, A. ;

Lee, K. H. ;

de Wit, M. ;

Cho, B. C. ;

Bourhaba, M. ;

Quantin, X. ;

Tokito, T. ;

Mekhail, T. ;

Planchard, D. ;

Kim, Y. -C. ;

Karapetis, C. S. ;

Hiret, S. ;

Ostoros, G. ;

Kubota, K. ;

Gray, J. E. ;

Paz-Ares, L. ;

de Castro Carpeno, J. ;

Wadsworth, C. ;

Melillo, G. ;

Jiang, H. ;

Huang, Y. ;

Dennis, P. A. ;

Ozguroglu, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20) :1919-1929

[5] Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non-Small-Cell Lung Cancer [J].

Auperin, Anne ;

Le Pechoux, Cecile ;

Rolland, Estelle ;

Curran, Walter J. ;

Furuse, Kiyoyuki ;

Fournel, Pierre ;

Belderbos, Jose ;

Clamon, Gerald ;

Ulutin, Hakki Cuneyt ;

Paulus, Rebecca ;

Yamanaka, Takeharu ;

Bozonnat, Marie-Cecile ;

Uitterhoeve, Apollonia ;

Wang, Xiaofei ;

Stewart, Lesley ;

Arriagada, Rodrigo ;

Burdett, Sarah ;

Pignon, Jean-Pierre .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (13) :2181-2190

[6] Stimulating Innate Immunity to Enhance Radiation Therapy-Induced Tumor Control [J].

Baird, Jason R. ;

Monjazeb, Arta M. ;

Shah, Omid ;

McGee, Heather ;

Murphy, William J. ;

Crittenden, Marka R. ;

Gough, Michael J. .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 99 (02) :362-373

[7] Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: A randomized phase II locally advanced multi-modality protocol [J].

Belani, CP ;

Choy, H ;

Bonomi, P ;

Scott, C ;

Travis, P ;

Haluschak, J ;

Curran, WJ .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) :5883-5891

[8] Phase II Study of Cetuximab in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small-Cell Lung Cancer: RTOG 0324 [J].

Blumenschein, George R., Jr. ;

Paulus, Rebecca ;

Curran, Walter J. ;

Robert, Francisco ;

Fossella, Frank ;

Werner-Wasik, Maria ;

Herbst, Roy S. ;

Doescher, Philip O. ;

Choy, Hak ;

Komaki, Ritsuko .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (17) :2312-2318

[9] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[10] Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study [J].

Bradley, Jeffrey D. ;

Paulus, Rebecca ;

Komaki, Ritsuko ;

Masters, Gregory ;

Blumenschein, George ;

Schild, Steven ;

Bogart, Jeffrey ;

Hu, Chen ;

Forster, Kenneth ;

Magliocco, Anthony ;

Kavadi, Vivek ;

Garces, Yolanda I. ;

Narayan, Samir ;

Iyengar, Puneeth ;

Robinson, Cliff ;

Wynn, Raymond B. ;

Koprowski, Christopher ;

Meng, Joanne ;

Beitler, Jonathan ;

Gaur, Rakesh ;

Curran, Walter, Jr. ;

Choy, Hak .

LANCET ONCOLOGY, 2015, 16 (02) :187-199

← 1 2 3 4 5 6 7 →